Takeaways: This notice of allowance shores up Anixa’s IP moat around its AMHR2‑targeted ovarian cancer vaccine and aligns Canada with its existing US patent protection. ...
Takeaways: Sunshine Biopharma’s approval for generic rivaroxaban (Xarelto) adds a high-volume, key anticoagulant to its Canadian portfolio and pairs with its existing generic apixaban to create ...
Takeaways: This acquisition turbocharges Hims & Hers’ Canada growth by giving it a ready-made weight-management business and local provider network, while it becomes the first Canadian...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
Takeaways: Novo Nordisk is defending branded Ozempic’s market share by narrowing the price gap with generic semaglutide for uninsured Canadians. That should help reduce switching to lower-cost a...
Takeaways: Ontario’s reimbursement of Braftovi is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
Takeaways: Brain Canada is using these Platform Support Grants to build durable infrastructure in Western Canada that can change how brain and mental health research is done, not just fund singl...
